CL2011002675A1 - Use of compounds derived from 9-purin-9-yl-3,4-dihydroxytetrahydrofuran-2-yl-methyl nitrate or sulfate to reduce intraocular pressure; ophthalmic pharmaceutical composition comprising the compounds; and ophthalmic formulation of topical use that includes them. - Google Patents
Use of compounds derived from 9-purin-9-yl-3,4-dihydroxytetrahydrofuran-2-yl-methyl nitrate or sulfate to reduce intraocular pressure; ophthalmic pharmaceutical composition comprising the compounds; and ophthalmic formulation of topical use that includes them.Info
- Publication number
- CL2011002675A1 CL2011002675A1 CL2011002675A CL2011002675A CL2011002675A1 CL 2011002675 A1 CL2011002675 A1 CL 2011002675A1 CL 2011002675 A CL2011002675 A CL 2011002675A CL 2011002675 A CL2011002675 A CL 2011002675A CL 2011002675 A1 CL2011002675 A1 CL 2011002675A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- ophthalmic
- dihydroxytetrahydrofuran
- purin
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 230000004410 intraocular pressure Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000699 topical effect Effects 0.000 title abstract 2
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
Abstract
Método para reducir la presión intraocular en seres humanos; composición farmacéutica oftálmica que comprende compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo; y formulación oftálmica de uso tópico que los comprende.Method to reduce intraocular pressure in humans; ophthalmic pharmaceutical composition comprising nitrate or sulfate derived compounds of 9-purin-9-yl-3,4-dihydroxytetrahydrofuran-2-yl-methyl; and ophthalmic formulation for topical use that includes them.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17465509P | 2009-05-01 | 2009-05-01 | |
| US21999009P | 2009-06-24 | 2009-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002675A1 true CL2011002675A1 (en) | 2012-06-01 |
Family
ID=43030847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002675A CL2011002675A1 (en) | 2009-05-01 | 2011-10-27 | Use of compounds derived from 9-purin-9-yl-3,4-dihydroxytetrahydrofuran-2-yl-methyl nitrate or sulfate to reduce intraocular pressure; ophthalmic pharmaceutical composition comprising the compounds; and ophthalmic formulation of topical use that includes them. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8470800B2 (en) |
| EP (1) | EP2424546B1 (en) |
| JP (1) | JP5778663B2 (en) |
| KR (1) | KR101757940B1 (en) |
| CN (1) | CN102413832B (en) |
| AU (1) | AU2010242943B2 (en) |
| BR (1) | BRPI1009971A2 (en) |
| CA (1) | CA2762064A1 (en) |
| CL (1) | CL2011002675A1 (en) |
| DK (1) | DK2424546T3 (en) |
| EA (1) | EA024042B1 (en) |
| ES (1) | ES2554684T3 (en) |
| HR (1) | HRP20151200T1 (en) |
| HU (1) | HUE028068T2 (en) |
| IL (1) | IL216081A (en) |
| MX (1) | MX2011011229A (en) |
| MY (1) | MY159244A (en) |
| NZ (1) | NZ596428A (en) |
| PL (1) | PL2424546T3 (en) |
| PT (1) | PT2424546E (en) |
| RS (1) | RS54378B1 (en) |
| SG (1) | SG175346A1 (en) |
| SI (1) | SI2424546T1 (en) |
| SM (1) | SMT201500295B (en) |
| WO (1) | WO2010127210A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008062567A1 (en) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid prodrugs and their use |
| DE102009006602A1 (en) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs |
| CA2774704A1 (en) * | 2009-10-26 | 2011-05-05 | Inotek Pharmaceuticals Corporation | Ophthalmic formulation and method of manufacture thereof |
| EA025415B1 (en) * | 2010-01-11 | 2016-12-30 | Инотек Фармасьютикалз Корпорейшн | Combination, kit and method of reducing intraocular pressure |
| PT2555775T (en) * | 2010-03-19 | 2017-02-01 | Inotek Pharmaceuticals Corp | Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure |
| LT2555776T (en) * | 2010-03-19 | 2017-04-25 | Inotek Pharmaceuticals Corporation | Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure |
| EP2569325A4 (en) | 2010-03-26 | 2013-10-09 | Inotek Pharmaceuticals Corp | METHOD FOR REDUCING INTRAOCULAR PRESSURE IN HUMANS USING N6-CYCLOPENTYLADENOSINE (CPA) DERIVATIVES OR CPA PRODRUGS |
| DE102010030688A1 (en) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituted dicyanopyridines and their use |
| US20120058983A1 (en) * | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
| US9278991B2 (en) * | 2012-01-26 | 2016-03-08 | Inotek Pharmaceuticals Corporation | Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof |
| CA2903114A1 (en) | 2013-03-15 | 2014-09-25 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
| EP3247715A1 (en) * | 2014-12-03 | 2017-11-29 | Inotek Pharmaceuticals Corporation | Methods of preventing, reducing or treating macular degeneration |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101010085B (en) | 2004-05-26 | 2012-12-26 | 伊诺泰克制药公司 | Purine derivatives as adenosine A1 receptor agonists and their usage |
| DE602005020286D1 (en) * | 2004-05-26 | 2010-05-12 | Inotek Pharmaceuticals Corp | PURE DERIVATIVES THAN ADENOSINE A 1 RECEPTOR AGONISTS AND METHOD FOR THE APPLICATION THEREOF |
| AU2006320578B2 (en) * | 2005-11-30 | 2013-01-31 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
| CA2774704A1 (en) * | 2009-10-26 | 2011-05-05 | Inotek Pharmaceuticals Corporation | Ophthalmic formulation and method of manufacture thereof |
| EA025415B1 (en) * | 2010-01-11 | 2016-12-30 | Инотек Фармасьютикалз Корпорейшн | Combination, kit and method of reducing intraocular pressure |
| PT2555775T (en) * | 2010-03-19 | 2017-02-01 | Inotek Pharmaceuticals Corp | Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure |
| LT2555776T (en) * | 2010-03-19 | 2017-04-25 | Inotek Pharmaceuticals Corporation | Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure |
-
2010
- 2010-04-30 CN CN201080018539.XA patent/CN102413832B/en not_active Expired - Fee Related
- 2010-04-30 HR HRP20151200TT patent/HRP20151200T1/en unknown
- 2010-04-30 RS RS20150782A patent/RS54378B1/en unknown
- 2010-04-30 JP JP2012508764A patent/JP5778663B2/en not_active Expired - Fee Related
- 2010-04-30 KR KR1020117025057A patent/KR101757940B1/en not_active Expired - Fee Related
- 2010-04-30 PL PL10770402T patent/PL2424546T3/en unknown
- 2010-04-30 EP EP10770402.5A patent/EP2424546B1/en active Active
- 2010-04-30 SG SG2011078151A patent/SG175346A1/en unknown
- 2010-04-30 MY MYPI2011004858A patent/MY159244A/en unknown
- 2010-04-30 EA EA201171339A patent/EA024042B1/en not_active IP Right Cessation
- 2010-04-30 WO PCT/US2010/033112 patent/WO2010127210A1/en not_active Ceased
- 2010-04-30 CA CA2762064A patent/CA2762064A1/en not_active Abandoned
- 2010-04-30 DK DK10770402.5T patent/DK2424546T3/en active
- 2010-04-30 MX MX2011011229A patent/MX2011011229A/en unknown
- 2010-04-30 ES ES10770402.5T patent/ES2554684T3/en active Active
- 2010-04-30 BR BRPI1009971A patent/BRPI1009971A2/en not_active IP Right Cessation
- 2010-04-30 PT PT107704025T patent/PT2424546E/en unknown
- 2010-04-30 US US12/771,289 patent/US8470800B2/en not_active Expired - Fee Related
- 2010-04-30 NZ NZ596428A patent/NZ596428A/en not_active IP Right Cessation
- 2010-04-30 SI SI201031070T patent/SI2424546T1/en unknown
- 2010-04-30 AU AU2010242943A patent/AU2010242943B2/en not_active Ceased
- 2010-04-30 HU HUE10770402A patent/HUE028068T2/en unknown
-
2011
- 2011-10-27 CL CL2011002675A patent/CL2011002675A1/en unknown
- 2011-11-01 IL IL216081A patent/IL216081A/en not_active IP Right Cessation
-
2013
- 2013-04-03 US US13/855,919 patent/US20130217643A1/en not_active Abandoned
-
2015
- 2015-11-30 SM SM201500295T patent/SMT201500295B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002675A1 (en) | Use of compounds derived from 9-purin-9-yl-3,4-dihydroxytetrahydrofuran-2-yl-methyl nitrate or sulfate to reduce intraocular pressure; ophthalmic pharmaceutical composition comprising the compounds; and ophthalmic formulation of topical use that includes them. | |
| DOP2019000005A (en) | 3-METIL PIRAZINAS 2,5-DISUSTITUIDAS AND 3-METIL PIRAZINAS 2,5,6-TRISUSTITUIDAS AS ALLOSTERIC INHIBITORS OF SHP2 | |
| DOP2010000304A (en) | COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME | |
| CR20130033A (en) | FORMULATIONS OF RIFAXIMINE AND USES OF THE SAME | |
| CL2012003281A1 (en) | Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis. | |
| CL2008002319A1 (en) | Compounds derived from pyrrolopyrimidine; pharmaceutical composition comprising said compounds; and its use to treat cancer. | |
| CL2011000527A1 (en) | Compounds derived from benzofuran; pharmaceutical composition that includes them; and their use in the treatment of hepatitis c. | |
| CL2015003801A1 (en) | Antibody formulations and methods | |
| CL2009001484A1 (en) | Glycinate salt of metformin; pharmaceutical composition comprising the salt; and its use to treat hyperglycemia. | |
| UY31673A1 (en) | "UREA HETEROCYCLIC DERIVATIVES AND METHODS OF USE OF THE SAME-211" | |
| MX353827B (en) | Forms of rifaximin and uses thereof. | |
| SV2010003559A (en) | SOME DERIVATIVES OF 2-PIRAZINONA AND ITS USE AS INHIBITORS OF ELASTASA DE LOS NEUTROFILOS | |
| AR047928A1 (en) | TETRAHYDROPIRIDOINDOL DERIVATIVES | |
| CL2014001158A1 (en) | Alkylated piperazine derivative compounds; pharmaceutical composition that includes them; process to prepare the pharmaceutical composition; kit and use in the treatment of immune disorders, cancer, cardiovascular diseases, inflammation, among others. | |
| CR20160222U (en) | SOLID FORMS OF ACID {[- (3- CHLOROPHENYL) -3- HYDROXIPIRIDIN -2-CARBONIL] AMINO} ACETIC, COMPOSITIONS, AND USES OF THE SAME | |
| CL2012003075A1 (en) | Pharmaceutical composition in pazopanib solution, stable and for ophthalmic use; method for the preparation of said solution. | |
| BRPI1106572B8 (en) | COMPOSITIONS COMPRISING A RETINOID AND AN NFKB INHIBITOR AND THEIR METHODS OF USE | |
| GT201000047A (en) | IMPROVEMENTS IN ORGANIC COMPOUNDS OR RELATED TO THE SAME | |
| UY34008A (en) | ? FORMS IN SOLID STATE OF HIV INHIBITOR, PHARMACEUTICAL COMPOSITION, USE OF THE SAME, AND PROCESSES TO PREPARE SUCH FORMS ?. | |
| UY35276A (en) | New compounds that inhibit the activity of Lp-PLA2 | |
| UY30215A1 (en) | CHROMANOL DERIVATIVES REPLACED, PROCEDURES FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
| CL2008002185A1 (en) | Pyrimidine derived compounds, phosphatidylinositol-3-kinase inhibitors; pharmaceutical composition comprising said compounds; and its use for the treatment of respiratory diseases, allergies, inflammation, cancer, among other diseases. | |
| SV2018005760A (en) | USEFUL AMINOTIAZOL DERIVATIVES AS ANTIVIRICAL AGENTS | |
| BR112013017953A2 (en) | PHARMACEUTICAL COMPOSITION, TOPICAL FORMULATION, METHOD, AND PHOTOSENSITIZING COMPOSITION | |
| PE20150167A1 (en) | (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL |